Clinical Observation of Docetaxel Combined with Oxaliplatin Regimen for Advanced Gastric Cancer_West China Medical Journal

Authors：

 HANYi-chao ,  PENGYe , YANGXiu-fang , XIENa

Department of Oncology, Harrison International Peace Hospital, Hengshui, Hebei 053000, P. R. China;

Corresponding?author：

PENGYe, Email: pengye666@sina.com

Keywords：

Docetaxel; Oxaliplatin; Chemotherapy; Advanced gastric cancer

DOI：

10.7507/1002-0179.20140620

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To evaluate the efficacy and safety of docetaxel (DOC) combined with oxaliplatin (OXA) regimen in the treatment of advanced gastric cancer. Methods Sixty patients with advanced gastric cancer treated in our hospital from January 2008 to January 2011 were randomly divided into two groups. The treatment group (n=30) was given DOC combined with OXA regimen. Patients in this group were treated with DOC 75 mg/m², ivgtt, d1; OXA 130 mg/m², ivgtt, d4; with 21 days as a cycle. The control group (n=30) was given DCF regimen. Patients in the control group were treated with DOC 75 mg/m², ivgtt, d1; cisplatin 75 mg/m², ivgtt, d1; calcium folinate 200/m², ivgtt, 2 h, d1-2; fluorouracil 400 mg/m², bolus 10 minutes, fluorouracil 600 mg/m² civ 22 h d1-2; also with 21 days as a cycle. All patients received two cycles of chemotherapy at least. The effective rate (complete remission+partial remission), adverse reactions, median survival time and quality of life were analyzed and compared between the two groups. Results The effective rates in the treatment group and the control group were 60.0% and 46.7% respectively, showing a non-significant difference (P>0.05). The appetite increasing rate (70.0% vs 43.3%), the weight gain rate (60.0% vs 33.3%), and the Karnofsky score improvement rate (63.3% vs 30.0%) of the treatment group were significantly higher than those of the control group (P<0.05). The adverse reactions were fewer in the treatment group, and most of them were between grade Ⅰ and Ⅱ. The median time of disease progression (5.8 months vs 5.6 months) and the median survival period (11.8 months vs 9.2 months) of the treatment group were longer than those in the control group. Conclusion DOC combined with OXA regimen is effective in treating advanced gastric cancer. It can significantly improve the quality of life of the patients, and it has fewer adverse reactions. Meanwhile, the median survival period is prolonged. DOC combined with OXA regimen is worth to be applied in clinic.

Citation： HANYi-chao, PENGYe, YANGXiu-fang, XIENa. Clinical Observation of Docetaxel Combined with Oxaliplatin Regimen for Advanced Gastric Cancer. West China Medical Journal, 2014, 29(11): 2055-2058. doi: 10.7507/1002-0179.20140620 Copy

1.	中國抗癌協會. 新編常見惡性腫瘤診治規范[M]. 北京:中國協和醫科大學出版社, 1999:105.
2.	Edge SB, Byrd DR, Compton CC, et al. AJCC cancer staging manual[M]. 7th ed. New York:Springer-Verlag, 2009:117-126.
3.	Ruiz-García V, Juan O, Pérez Hoyos S, et al. Megestrol acetate:a systematic review usefulness about the weight gain in neoplastic patients with cachexia[J]. Med Clin (Barc), 2002, 119(5):166-170.
4.	胡章華, 毛紹蓉. XELOX化療方案用于老年晚期胃癌患者治療的臨床觀察[J]. 重慶醫學, 2013, 42(2):156-159.
5.	Ben Aharon I, Purim O, Kundel Y, et al. The combination of docetaxel, cisplatin, and 5-fluorouracil in advanced gastric cancer:a single-institution experience[J]. Anticancer Drugs, 2012, 23(3):313-320.
6.	張昉, 陳雅敏, 荊超, 等. 改良DCF方案與FOLFOX 4方案治療晚期胃癌的臨床療效[J]. 臨床腫瘤學雜志, 2014, 19(3):231-234.
7.	Chi Y, Ren JH, Yang L, et al. Phase Ⅱ clinical study on the modified DCF regimen for treatment of advanced gastric carcinoma[J]. Chin Med J (Engl), 2011, 124(19):2997-3002.
8.	吳芳, 張弘綱. 多西紫杉醇在晚期胃癌的臨床應用[J]. 癌癥進展, 2007, 5(3):276-281, 289.
9.	金懋林. 最新胃癌化學治療方案[M]. 北京:北京科學技術出版社, 2003:15-16.
10.	呂慧芳, 張延新, 韓黎麗, 等. 奧沙利鉑聯合替吉奧或卡培他濱治療老年晚期胃癌的臨床觀察[J]. 中國醫藥導報, 2012, 9(23):61-63.
11.	Kondoh C, Takahari D, Shitara K, et al. Efficacy of docetaxel in patients with paclitaxel-resistant advanced gastric cancer[J]. Gan To Kagaku Ryoho, 2012, 39(10):1511-1515.
12.	Choi YH, Oh SC, Kim JS, et al. A phase Ⅱ study of docetaxel and oxaliplatin combination in recurrent gastric cancer patients after fluoropyrimidine and/or cisplatin adjuvant treatment:a Korean Cancer Study Group Protocol ST06-02[J]. Cancer Chemother Pharmacol, 2012, 70(5):665-672.
13.	粱進, 畢清, 楊潤祥. 多西他賽聯合奧沙利鉑治療進展期胃癌的臨床觀察[J]. 實用癌癥雜志, 2007, 22(5):501-502.
14.	陳紹俊, 黃海欣, 黃東寧, 等. 多西紫杉醇聯合奧沙利鉑每周療法治療30例高齡晚期胃癌的臨床觀察[J]. 四川醫學, 2009, 30(11):1725-1727.
15.	葉珩, 錢科卿, 朱穎蔚. 多西紫杉醇聯合氟尿嘧啶和奧沙利鉑治療晚期胃癌的臨床觀察[J]. 臨床腫瘤學雜志, 2007, 12(10):763-764, 770.
16.	金建華, 李獻文, 王芳, 等. 多西紫杉醇聯合奧沙利鉑、卡培他濱與FOLFOX4方案治療晚期胃癌療效比較[J]. 腫瘤防治研究, 2007, 34(11):873-876.

1. 中國抗癌協會. 新編常見惡性腫瘤診治規范[M]. 北京:中國協和醫科大學出版社, 1999:105.
2. Edge SB, Byrd DR, Compton CC, et al. AJCC cancer staging manual[M]. 7th ed. New York:Springer-Verlag, 2009:117-126.
3. Ruiz-García V, Juan O, Pérez Hoyos S, et al. Megestrol acetate:a systematic review usefulness about the weight gain in neoplastic patients with cachexia[J]. Med Clin (Barc), 2002, 119(5):166-170.
4. 胡章華, 毛紹蓉. XELOX化療方案用于老年晚期胃癌患者治療的臨床觀察[J]. 重慶醫學, 2013, 42(2):156-159.
5. Ben Aharon I, Purim O, Kundel Y, et al. The combination of docetaxel, cisplatin, and 5-fluorouracil in advanced gastric cancer:a single-institution experience[J]. Anticancer Drugs, 2012, 23(3):313-320.
6. 張昉, 陳雅敏, 荊超, 等. 改良DCF方案與FOLFOX 4方案治療晚期胃癌的臨床療效[J]. 臨床腫瘤學雜志, 2014, 19(3):231-234.
7. Chi Y, Ren JH, Yang L, et al. Phase Ⅱ clinical study on the modified DCF regimen for treatment of advanced gastric carcinoma[J]. Chin Med J (Engl), 2011, 124(19):2997-3002.
8. 吳芳, 張弘綱. 多西紫杉醇在晚期胃癌的臨床應用[J]. 癌癥進展, 2007, 5(3):276-281, 289.
9. 金懋林. 最新胃癌化學治療方案[M]. 北京:北京科學技術出版社, 2003:15-16.
10. 呂慧芳, 張延新, 韓黎麗, 等. 奧沙利鉑聯合替吉奧或卡培他濱治療老年晚期胃癌的臨床觀察[J]. 中國醫藥導報, 2012, 9(23):61-63.
11. Kondoh C, Takahari D, Shitara K, et al. Efficacy of docetaxel in patients with paclitaxel-resistant advanced gastric cancer[J]. Gan To Kagaku Ryoho, 2012, 39(10):1511-1515.
12. Choi YH, Oh SC, Kim JS, et al. A phase Ⅱ study of docetaxel and oxaliplatin combination in recurrent gastric cancer patients after fluoropyrimidine and/or cisplatin adjuvant treatment:a Korean Cancer Study Group Protocol ST06-02[J]. Cancer Chemother Pharmacol, 2012, 70(5):665-672.
13. 粱進, 畢清, 楊潤祥. 多西他賽聯合奧沙利鉑治療進展期胃癌的臨床觀察[J]. 實用癌癥雜志, 2007, 22(5):501-502.
14. 陳紹俊, 黃海欣, 黃東寧, 等. 多西紫杉醇聯合奧沙利鉑每周療法治療30例高齡晚期胃癌的臨床觀察[J]. 四川醫學, 2009, 30(11):1725-1727.
15. 葉珩, 錢科卿, 朱穎蔚. 多西紫杉醇聯合氟尿嘧啶和奧沙利鉑治療晚期胃癌的臨床觀察[J]. 臨床腫瘤學雜志, 2007, 12(10):763-764, 770.
16. 金建華, 李獻文, 王芳, 等. 多西紫杉醇聯合奧沙利鉑、卡培他濱與FOLFOX4方案治療晚期胃癌療效比較[J]. 腫瘤防治研究, 2007, 34(11):873-876.

Previous Article
Relationship between Clinicopathological Characteristics and Invasion Depth of Early Gastric Cancer
Next Article
Analysis of Clinical Laboratory Tests for Benign Prostatic Hyperplasia

West China Medical Journal

Clinical Observation of Docetaxel Combined with Oxaliplatin Regimen for Advanced Gastric Cancer

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content